Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, Devereux S, Lovell R, Chopra R, Marks DI, Mackinnon S, Milligan DW; British Society of Blood and Marrow Transplantation. Delgado J, et al. Among authors: lovell r. Blood. 2006 Feb 15;107(4):1724-30. doi: 10.1182/blood-2005-08-3372. Epub 2005 Oct 20. Blood. 2006. PMID: 16239425 Free article. Clinical Trial.
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S. Delgado J, et al. Among authors: lovell r. Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001. Biol Blood Marrow Transplant. 2008. PMID: 18940684 Free article.
Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis.
Delgado J, Pillai S, Phillips N, Brunet S, Pratt G, Briones J, Lovell R, Martino R, Ewing J, Sureda A, Milligan DW, Sierra J. Delgado J, et al. Among authors: lovell r. Ann Oncol. 2009 Dec;20(12):2007-12. doi: 10.1093/annonc/mdp259. Epub 2009 Jul 12. Ann Oncol. 2009. PMID: 19596701 Free article.
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C. Nikolousis E, et al. Among authors: lovell r. Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5. Leuk Res. 2013. PMID: 23395505 Clinical Trial.
Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting.
Marzolini MAV, Mehra V, Thomson KJ, Tholouli E, Bloor AJC, Parker A, Lovell R, Orchard K, Publicover A, Nicholson E, Snowden JA, Byrne J, Khan A, Gilleece MH, Errico G, Lozano S, Hurst E, Duncan N, Pirrie J, Crea P, Carpenter B, Pagliuca A, Peggs KS. Marzolini MAV, et al. Among authors: lovell r. Blood Adv. 2021 Nov 9;5(21):4500-4503. doi: 10.1182/bloodadvances.2021005637. Blood Adv. 2021. PMID: 34614515 Free PMC article. No abstract available.
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Kanellopoulos A, Kaparou M, Xenou E, Paneesha S, Kishore B, Lovell R, Holder K, Suhr J, Baker L, Ryan L, Nikolousis E. Kanellopoulos A, et al. Among authors: lovell r. Bone Marrow Transplant. 2018 Dec;53(12):1518-1521. doi: 10.1038/s41409-018-0297-z. Epub 2018 Aug 16. Bone Marrow Transplant. 2018. PMID: 30116019
374 results